Source-grounded facts extracted from GALECTIN THERAPEUTICS INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
GALECTIN THERAPEUTICS INC reported three months ended March 31, 2026 results: net income $5.1 million, or ($0.08) per share, EPS ($0.08) per share.
“For the quarter ended quarter ended March 31, 2026, the Company reported a net loss applicable to common stockholders of $5.1 million, or ($0.08) per share”
GALECTIN THERAPEUTICS INC reported financial results for the year ended December 31, 2025.
“Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2025.”
GALECTIN THERAPEUTICS INC entered into December 2025 Supplemental Line of Credit Agreement with Richard E. Uihlein valued at up to $10.00 million line of credit (effective 2025-12-19).
“On December 19, 2025, Galectin Therapeutics Inc. (the “Company”) and Richard E. Uihlein (the “Lender”) entered into a Line of Credit Letter Agreement (the “December 2025 Supplemental Line of Credit Agreement”), pursuant to which the Lender shall provide the Company a line of credit of up to $10.00 million (the “Line of Credit”) to finance the Company’s working capital needs.”
Pol Boudes resigned as Chief Medical Officer at GALECTIN THERAPEUTICS INC.
“Dr. Jamil succeeds Dr. Pol Boudes as Chief Medical Officer of the Company, who resigned on July 26, 2024. Dr. Boudes’s last day of employment with the Company is August 1, 2024.”
Khurram Jamil changed role as Chief Medical Officer at GALECTIN THERAPEUTICS INC.
“On August 1, 2024, Galectin Therapeutics Inc. (the “Company”) announced the promotion of Dr. Khurram Jamil to Chief Medical Officer effective immediately.”
GALECTIN THERAPEUTICS INC reported the quarter ended March 31, 2024 results: net income net loss of $11.5 million, EPS ($0.19) per share.
“For the quarter ended quarter ended March 31, 2024, the Company reported a net loss applicable to common stockholders of $11.5 million, or ($0.19) per share, compared to a net loss applicable to common stockholders of $11.5 million, or ($0.19) per share for the quarter ended March 31, 2023.”
GALECTIN THERAPEUTICS INC reported the year ended December 31, 2023 results: net income net loss applicable to common stockholders of $44.8 million, or ($0.74) per share, EPS $(0.74).
“For the year ended December 31, 2023, the Company reported a net loss applicable to common stockholders of $44.8 million, or ($0.74) per share, compared to a net loss applicable to common stockholders of $38.9 million, or ($0.65) per share for the year ended December 31, 2022.”
GALECTIN THERAPEUTICS INC shareholders approved Approved an amendment to our 2019 Omnibus Equity Incentive Plan to reserve an additional 3,000,000 shares for issuance under the plan at the 2023-12-07 meeting.
“Approved an amendment to our 2019 Omnibus Equity Incentive Plan to reserve an additional 3,000,000 shares for issuance under the plan. Votes For Votes Against Votes Abstain Broker Non-Votes 23,901,293 1,923,578 186,751 18,910,166”
GALECTIN THERAPEUTICS INC shareholders approved Ratification of the selection of Cherry Bekaert LLP as the independent registered public accounting firm for the Company for the year ending December 31, 2023 at the 2023-12-07 meeting.
“Ratification of the selection of Cherry Bekaert LLP as the independent registered public accounting firm for the Company for the year ending December 31, 2023 Votes For Votes Against Votes Abstain 44,481,830 252,254 187,704”
GALECTIN THERAPEUTICS INC shareholders approved Election of Directors at the 2023-12-07 meeting.
“Election of Directors Name Votes For Votes Withheld Broker Non-Votes Gilbert F. Amelio, Ph.D. 24,856,340 1,155,282 18,910,166”
GALECTIN THERAPEUTICS INC reported the three months ended September 30, 2023 results: net income net loss applicable to common stockholders of $14.0 million, or ($0.24) per share, EPS ($0.24) per share.
“For the three months ended September 30, 2023, the Company reported a net loss applicable to common stockholders of $14.0 million, or ($0.24) per share, compared to a net loss applicable to common stockholders of $8.6 million, or ($0.14) per share for the three months ended September 30, 2022.”
GALECTIN THERAPEUTICS INC reported financial results for nine months ended September 30, 2023.
“Galectin Therapeutics Inc. (“Galectin Therapeutics”) issued a press release announcing its results of operations and financial condition as of and for the three and nine months ended September 30, 2023”
GALECTIN THERAPEUTICS INC reported three months ended September 30, 2023 results: net income net loss applicable to common stockholders of $14.0 million, EPS ($0.24) per share.
“For the three months ended September 30, 2023, the Company reported a net loss applicable to common stockholders of $14.0 million, or ($0.24) per share”
GALECTIN THERAPEUTICS INC reported financial results for the six months ended June 30, 2023.
“announcing its results of operations and financial condition as of and for the three and six months ended June 30, 2023”
GALECTIN THERAPEUTICS INC reported the three months ended June 30, 2023 results: net income a net loss applicable to common stockholders of $9.2 million, or ($0.15) per share, EPS ($0.15) per share.
“For the three months ended June 30, 2023, the Company reported a net loss applicable to common stockholders of $9.2 million, or ($0.15) per share”
GALECTIN THERAPEUTICS INC reported three months ended March 31, 2023 results: net income net loss applicable to common stockholders of $11.5 million, or ($0.19) per share, EPS ($0.19) per share.
“Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2023 and Provides Business Update”
GALECTIN THERAPEUTICS INC reported the year ended December 31, 2022 results: net income $38.9 million, EPS ($0.65) per share.
“For the year ended December 31, 2022, the Company reported a net loss applicable to common stockholders of $38.9 million, or ($0.65) per share”
GALECTIN THERAPEUTICS INC shareholders approved To vote on a non-binding advisory resolution to approve executive compensation at the 2022-12-01 meeting.
“To vote on a non-binding advisory resolution to approve executive compensation . Votes For Votes Against Votes Abstain Broker Non-Votes 16,271,959 1,450,200 428,140 18,758,920”
GALECTIN THERAPEUTICS INC shareholders approved Authorize and approve for purposes of complying with Nasdaq Listing Rule 5635, the issuance of more than 20% of our issued and outstanding shares of common stock in connection with our line of credit provided by Richard E. Uihlein, our Chairman of the Board of Directors. at the 2022-12-01 meeting.
“Authorize and approve for purposes of complying with Nasdaq Listing Rule 5635, the issuance of more than 20% of our issued and outstanding shares of common stock in connection with our line of credit provided by Richard E. Uihlein, our Chairman of the Board of Directors. The number of shares to be issued includes a maximum of 20,000,000 common shares in exchange for $60,000,000 for the principal of the line of credit, 1,700,000 of common shares for stock purchase warrants issued in connection with the line of credit, and common shares issuable in exchange for accrued interest on the line of credit. Votes For Votes Against Votes Abstain Broker Non-Votes 16,845,581 1,146,064 158,654 18,758,920”
GALECTIN THERAPEUTICS INC shareholders approved Ratification of the selection of Cherry Bekaert LLP as the independent registered public accounting firm for the Company for the year ending December 31, 2022 at the 2022-12-01 meeting.
“Ratification of the selection of Cherry Bekaert LLP as the independent registered public accounting firm for the Company for the year ending December 31, 2022 Votes For Votes Against Votes Abstain 36,267,085 370,624 271,510”
GALECTIN THERAPEUTICS INC shareholders approved Election of Directors at the 2022-12-01 meeting.
“Election of Directors Name Votes For Votes Withheld Broker Non-Votes Gilbert F. Amelio, Ph.D. 16,657,514 1,492,785 18,758,920 James C. Czirr 17,108,078 1,042,221 18,758,920 Kary Eldred 17,277,004 873,295 18,758,920 Kevin D. Freeman 16,987,116 1,163,183 18,758,920 Joel Lewis 17,492,649 657,650 18,758,920 Gilbert S. Omenn, M.D., Ph.D. 17,274,427 875,872 18,758,920 Marc Rubin, M.D. 16,865,340 1,284,959 18,758,920 Elissa J. Schwartz, Ph.D. 17,541,115 609,184 18,758,920 Harold H. Shlevin, Ph.D. 17,361,708 788,591 18,758,920 Richard E. Uihlein, Chairman 17,611,340 538,959 18,758,920 Richard A. Zordani 17,396,959 753,340 18,758,920”
GALECTIN THERAPEUTICS INC reported the three months ended September 30, 2022 results: net income $8.6 million, EPS ($0.14) per share.
“For the three months ended September 30, 2022, the Company reported a net loss applicable to common stockholders of $8.6 million, or ($0.14) per share”
GALECTIN THERAPEUTICS INC reported the three months ended March 31, 2022 results: net income net loss applicable to common stockholders of $9.9 million, EPS ($0.17) per share.
“For the three months ended March 31, 2022, the Company reported a net loss applicable to common stockholders of $9.9 million, or ($0.17) per share”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.